Pilot clinical study of Adacolumn cytapheresis in patients with systemic lupus erythematosus

Rheumatology International

Volumn 26, Issue 5, 2006, Pages 409-415

  Soerensen, Helmut ^a   Schneidewind Mueller, Jana Maria ^c   Lange, Doris ^b   Kashiwagi, Nobuhito ^d,f,g   Franz, Marita ^d   Yokoyama, Takashi ^d   Ramlow, Wolfgang ^e  

^a Waldfriede Hospital   (Germany)

^b IFTA Institute for Therapeutic Apheresis   (Germany)

^c Dialysis Center   (Germany)

^d Otsuka Frankfurt Research Institute GmbH   (Germany)

^e Dialysis Group North   (Germany)

^f JAPAN IMMUNORESEARCH LABORATORIES   (Japan)

^g KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Adacolumn; Cytapheresis; Systemic lupus erythematosus

Indexed keywords

ADULT; AGED; ALOPECIA; ARTHRITIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CYTAPHERESIS; DISEASE CLASSIFICATION; EXTRACORPOREAL CIRCULATION; FEMALE; GRANULOCYTE; HEMODIALYSIS; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; MEDICAL INSTRUMENTATION; MONOCYTE; MULTICENTER STUDY; MUSCULOSKELETAL SYSTEM; PILOT STUDY; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

ADULT; AGED; ALOPECIA AREATA; ARTHRITIS; CELL SEPARATION; FEMALE; GRANULOCYTES; HUMANS; LEUKAPHERESIS; LEUKOCYTE COUNT; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; MONOCYTES; PILOT PROJECTS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 33644629583     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-005-0031-1     Document Type: Article

References (26)

1. Davidson A, Diamond B (2001) Autoimmune diseases. N Engl J Med 345:340-345
2. Sturfelt G, Bengstsson A, Klint C, Nived O, Sjöholm A, Truedsson L (2000) Novel roles of complement in systemic lupus erythematosus-hypothesis for a pathogenetic vicious circle. J Rheumatol 27:661-663
3. Dar O, Salaman MR, Seifert MH, Isenberg DA (1988) B-lymphocyte activation in systemic lupus erythematosus: spontaneous production of IgG antibodies to DNA and environmental antigens in cultures of blood mononuclear cells. Clin Exp Immunol 73:430-435
4. high plasma cells and disease activity in systemic lupus erythematosus. Lupus 13:283-289
5. Khan IU, Tsokos GC, Kammer GM (2003) Abnormal B-cell signal transduction in systemic lupus erythematosus. Curr Dir Autoimmun 6:89-104
6. Kumagai S, Sredni B, House S, Steinberg AD, Green I (1982) Defective regulation of B-lymphocyte colony formation in patients with systemic lupus erythematosus. J Immunol 128:258-262
7. Nielsen CH, Rasmussen JM, Voss A, Junker P, Leslie RG (1998) Diminished ability of erythrocytes from patients with systemic lupus erythematosus to limit opsonized immune complex deposition on leukocytes and activation of granulocytes. Arthritis Rheum 41:613-622
8. Badsha H, Kong KO, Lian TY, Chan SP, Edwards CJ, Chng HH (2002) Low-dose pulse methylprednisolone for systemic lupus erythematosus flares is efficacious and has a decreased risk of infectious complications. Lupus 11:508-513
9. Abu-Shakra M, Urowitz MB, Gladman DD, Gough J (1995) Mortality studies in systemic lupus erythematosus. Results from a single center. I. causes of death. J Rheumatol 22:1259-1264
10. Martin F, Lauwerys B, Lefebvre C, Devogelaer JP, Houssiau FA (1997) Side-effects of intravenous cyclophosphamide pulse therapy. Lupus 6:254-257
11. Jones JV, Robinson MF, Parciany RK, Layfer LF, McLeod B (1981) Therapeutic plasmapheresis in systemic lupus erythematosus. Effect on immune complexes and antibodies to DNA. Arthritis Rheum 24:1113-1120
12. Lewis EJ, Hunsicker LG, Lan SP, Rohde RD, Lachin JM (1992) A controlled trial of plasmapheresis therapy in severe lupus nephritis. The lupus nephritis collaborative study group. N Engl J Med 326:1373-1379
13. Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, Sloand JA, Rosenblatt J, Sanz I (2004) B-cell depletion as a novel treatment for systemic lupus erythematosus. Arthritis Rheum 50:2580-2589
14. Boumpas DT, Furie R, Manzi S, Illei GG, Wallace DJ, Balow JE, Vaishnaw A (2003) BG9588 Lupus nephritis trial group. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 48:719-727
15. Hiraish K, Takeda Y, Shiobara N, Shibusawa H, Jimma F, Kahiwagi N, Saniabadi AR, Adachi M (2003) Studies on the mechanisms of leukocyte adhesion to cellulose acetate beads: an in vitro model to assess the efficacy of cellulose acetate carrier-based granulocyte and monocyte adsorptive apheresis. Ther Apher Dial 7(3):334-340
16. Kashiwagi N, Hirata I, Kasukawa R (1998) A role for granulocyte and monocyte apheresis in the treatment of rheumatoid arthritis. Ther Apher 2:134-141
17. Kashiwagi N, Sugimura K, Koiwai H, Yamamoto H, Yoshikawa T, Saniabadi AR, Adachi M, Shimoyama T (2002) Immunomodulatory effects of granulocyte and monocyte adsorption apheresis as a treatment for patients with ulcerative colitis. Dig Dis Sci 47:1334-1341
18. Shimoyama T, Sawada K, Hiwatashi N, Sawada T, Matsueda K, Munakata A, Asakura H, Tanaka T, Kasukawa R, Kimura K, Suzuki Y, Nagamachi Y, Muto T, Nagawa H, Iizuka B, Baba S, Nasu M, Kataoka T, Kashiwagi N, Saniabadi AR (2001) Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study. J Clin Apher 16:1-9
19. Kanekura T, Maruyama I, Kanzaki (2002) Granulocyte and monocyte adsorption apheresis for pyoderma gangrenosum. J Am Acad Dermatol 47:320-321
20. Saniabadi AR, Hanai H, Takeuchi K, Umemura K, Nakashima M, Adachi T, Shima C, Bjarnason I, Lofberg R (2003) Adocolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory diseases associated with leukocytes. Ther Apher Dial 7:48-59
21. Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725
22. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH (1992) Deviation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 35:630-638
23. Uesugi H, Ozaki S, Sobajima J, Osakada F, Shirakawa H, Yoshida M, Nakao K (1998) Prevalence and characterization of novel pANCA, antibodies to the high mobility group non-histone chromosomal proteins HMG1 and HMG2, in systemic rheumatic diseases. J Rheumatol 25:703-709
24. Hashimoto Y, Nakano K, Yoshinoya S, Tanimoto K, Itoh K (1992) Endothelial cell destruction by polymorphonuclear leukocytes incubated with sera from patients with systemic lupus erythematosus. Scan J Rheumatol 21:209-214
25. Kashiwagi N, Nakano M, Saniabadi AR, Adachi M, Yoshikawa T (2002) Anti-inflammatory effect of granulocyte and monocyte adsorption apheresis in a rabbit model of immune arthritis. Inflammation 26:199-205
26. Kanekura T, Hashiguchi T, Mera Y, Katahira A, Nakamura I, Maruyama I, Kanzaki T (2004) Improvement of SLE skin rash with granulocyte and monocyte adsorption apheresis. Dermatology 208:79-80